Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy

Neurology

Volumn 78, Issue 17, 2012, Pages 1309-1314

  De Pasquale, L ^a   D'Amico, A ^a   Verardo, M ^a   Petrini, S ^a   Bertini, E ^a   De Benedetti, F ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; JUVENILE DERMATOMYOSITIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MUSCLE BIOPSY; MUSCLE STRENGTH; NORTH STAR AMBULATORY ASSESSMENT SCORE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SCORING SYSTEM;

EID: 84860741378     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182518302     Document Type: Article

References (38)

1. Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J, Grange RW. Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am J Phys Med Rehabil 2009;88:502-522.
2. Wagner KR. Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics 2008;5:583-591.
3. Pescatori M, Broccolini A, Minetti C, et al. Gene expression profiling in the early phases of DMD: A constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J 2007;21:1210-1226. (Pubitemid 46495710)
4. Griggs RC, Moxley RT 3rd, Mendell JR, et al. Prednisone in Duchenne dystrophy. a randomized, controlled trial defining the time course and dose response: Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991;48:383-388.
5. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;1:CD003725.
6. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: Study of long-term effect. Muscle Nerve 1994;17:386-391. (Pubitemid 24096533)
7. Cua DJ, Tato CM. Innate IL-17-producing cells: The sentinels of the immune system. Nat Rev Immunol;10:479-489.
8. Torchinsky MB, Blander JM. T helper 17 cells: Discovery, function, and physiological trigger. Cell Mol Life Sci;67: 1407-1421.
9. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. Immunology;129:311-321.
10. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-1861. (Pubitemid 47240944)
11. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52:65-70. (Pubitemid 36020767)
12. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-508. (Pubitemid 34546753)
13. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-155. (Pubitemid 351186376)
14. Zhao L, Qiu de K, Ma X. Th17 cells: The emerging reciprocal partner of regulatory T cells in the liver. J Dig Dis;11: 126-133.
15. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238.
16. Buckner JH. Mechanisms of impaired regulation by CD4+CD25+Foxp3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849-859.
17. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. Foxp3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490-500.
18. Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27. (Pubitemid 44116697)
19. Mazzone E, Martinelli D, Berardinelli A, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010;20:712-716.
20. Khanna S, Reed AM. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve 2010;41:581-592.
21. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1β on muscle cells: Arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003;137:125-133. (Pubitemid 36351574)
22. Tournadre A, Porcherot M, Cherin P, Marie I, Hachulla E, Miossec P. Th1 and Th17 balance in inflammatory myopathies: Interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 2009;46:297-301.
23. Bilgic H, Ytterberg S, McNallan K, et al. IL-17 and IFNregulated genes and chemokines as biomarkers of disease activity in inflammatory myopathies. Arthritis Rheum 2008;58:1.
24. Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 2009;60:2505-2512.
25. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002;46:802-805. (Pubitemid 34214263)
26. Hofstetter HH, Ibrahim SM, Koczan D, et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005;237: 123-130. (Pubitemid 43117208)
27. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177:566-573. (Pubitemid 43939170)
28. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-659. (Pubitemid 38198849)
29. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-6177. (Pubitemid 37467240)
30. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203: 2673-2682. (Pubitemid 44833343)
31. Sonderegger I, Rohn TA, Kurrer MO, et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2006;36:2849-2856. (Pubitemid 44782558)
32. Yoshimura T, Sonoda KH, Miyazaki Y, et al. Differential roles for IFN-γ and IL-17 in experimental autoimmune uveoretinitis. Int Immunol 2008;20:209-214. (Pubitemid 351234388)
33. Finnerty CC, Przkora R, Herndon DN, Jeschke MG. Cytokine expression profile over time in burned mice. Cytokine 2009;45:20-25.
34. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-β. J Clin Invest 2009;119:1583-1594.
35. Pegoraro E, Hoffman EP, Piva L, et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011;76:219-226.
36. Cantor H, Shinohara ML. Regulation of T-helper-cell lineage development by osteopontin: The inside story. Nat Rev Immunol 2009;9:137-141.
37. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008;181: 7480-7488.
38. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009; 18:482-496.